Summary Box: Lilly pitches plan for patent woes

LOOMING TROUBLE: Drugmaker Eli Lilly & Co. will lose patent protection for its top-selling drug, the antipsychotic Zyprexa, in October. In the next two years, the drugmaker will lose U.S. patents protecting drugs that produced 46 percent of its 2010 revenue.

Continue Reading →

Comments are closed.